share_log

CompuMed Announces Purchase of Shares Held by VI Capital and Changes in the Board of Directors

CompuMed Announces Purchase of Shares Held by VI Capital and Changes in the Board of Directors

CompuMed 宣佈收購 VI Capital 持有的股份以及董事會變動
Accesswire ·  2023/06/13 04:30

LOS ANGELES, CA / ACCESSWIRE / June 12, 2023 / CompuMed, Inc. (OTC Pink:CMPD), a leader in providing diagnostic telemedicine, is announcing the purchase of CompuMed shares held by V.I. Capital Fund, a Washington Limited Partnership (the Fund) as well as David Pointer's resignation as a Director of CompuMed.

加利福尼亞州洛杉磯/ACCESSWIRE/2023年6月12日/亞洲網加利福尼亞州聖克拉拉8月23日電診斷遠端醫療領域的領先供應商電腦醫療公司(場外交易代碼:CMPD)宣佈,將購買VI.資本基金、華盛頓有限合夥企業(該基金)持有的電腦醫療公司股票,並宣佈David·珀特辭去董事公司的職務。

Prior to the repurchase, the Fund owned 425,403 shares of CompuMed, or 25.3% of the 1,678,707 shares outstanding in total. David Pointer, on behalf of the Fund's general partner, notified the Corporation of the Fund's desire to liquidate certain investment positions including CompuMed. The Fund decided to give its limited partners the choice of receiving either cash or their pro-rata shares held in the Fund. CompuMed offered the Fund $2.00 per share for CompuMed shares being sold from the Fund. Limited partners opted to retain 63,235 CompuMed shares. The remaining 362,168 shares are being purchased by CompuMed for the agreed price of $2.00 per share at a total cost to CompuMed of $724,336. As previously disclosed in annual reports to Stockholders, the Board authorized repurchases of shares at an expense of up to $1,000,000. The Corporation will retire the repurchased shares.

在回購之前,該基金擁有425,403股CompuMed股票,佔總流通股1,678,707股的25.3%。David·指標代表基金的普通合夥人通知本公司,基金希望結清包括CompuMed在內的某些投資頭寸。基金決定向其有限責任合夥人提供現金或按比例持有基金股份的選擇。CompuMed向基金出價每股2.00美元,以換取基金出售的CompuMed股票。有限合夥人選擇保留63,235股CompuMed股票。剩餘的362,168股將由CompuMed以每股2.00美元的協議價格收購,CompuMed的總成本為724,336美元。正如之前在提交給股東的年度報告中披露的那樣,董事會授權回購股份,費用最高可達1,000,000美元。該公司將註銷回購的股份。

Both David Pointer and Lee Keddie are investors in the Fund. Mr. Keddie is the CEO of CompuMed and both he and Mr. Pointer are Directors of CompuMed. Both Mr. Keddie and Mr. Pointer recused themselves from the Corporation's decision to offer $2.00 per share for shares held by the Fund. That decision was made by Loren Den Herder, the Corporation's third and only independent Director and based on advice from outside counsel and members of management other than Mr. Keddie. Likewise, Mr. Keddie disclosed to CompuMed that he abstained from voting with the Fund's partners and instead informed the limited partners that he would sell shares in direct proportion to the amount sold by the Fund, which resulted in Mr. Keddie retaining 6,584 shares in CompuMed previously held through the Fund. Mr. Pointer elected to sell his entire position in CompuMed shares held though the Fund, though he still holds shares that he purchased directly.

David指標和李凱迪都是該基金的投資者。凱迪先生是CompuMed公司的首席執行官,他和波特先生都是CompuMed公司的董事。凱迪先生和波恩特先生都回避了公司提出每股2美元收購基金所持股份的決定。這一決定是由公司第三家也是唯一一家獨立董事公司Loren Den Herder根據外部法律顧問和凱迪先生以外的管理層成員的建議做出的。同樣,Keddie先生向CompuMed透露,他放棄了與基金合夥人一起投票,而是通知有限合夥人,他將按基金出售的金額直接出售股份,這導致Keddie先生保留了以前通過基金持有的6,584股CompuMed股份。波特爾選擇出售他通過該基金持有的全部CompuMed股票,但他仍持有直接購買的股票。

Following the share repurchase, Mr. Pointer resigned his position as a Chairman and Director of CompuMed. The corporation greatly appreciates his leadership and guidance as Chairman over the past seven years. A separate announcement will address filling the vacancy on the Board. In the interim, Loren Den Herder will serve as Chairman of the Board of Directors.

股票回購完成後,指標辭去了他在CompuMed董事長和董事的職務。公司非常感謝他在過去七年中作為董事長所發揮的領導和指導作用。另一份公告將涉及填補董事會空缺的問題。在此期間,Loren Den Herder將擔任董事會主席。

Inquiries about this can be sent to investorrelations@compumedinc.com or contact Laura Carroll at 310-258-5002.

有關這方面的查詢,請發送至InvestorRelationship@Compumedinc.com或聯繫勞拉·卡羅爾,電話:310-258-5002。

About CompuMed, Inc.

CompuMed公司簡介

CompuMed, Inc. (OTCPink:CMPD) Diagnostic Telemedicine services provide patients with the highest level of clinical care at reduced costs. Its telecardiology and teleradiology offerings provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities anywhere in the world. The Corporation has been in business over 26 years and services over 1,000 clinical settings. CompuMed is headquartered in Los Angeles, CA. Visit CompuMed at .

CompuMed公司(OTCPINK:CMPD)診斷遠端醫療服務以更低的成本為患者提供最高水準的臨床護理。它的遠端心血管學和遠端放射學產品通過基於雲的技術和集成的醫療設備向世界任何地方的醫療機構提供即時訪問美國委員會認證的專家。該公司已有26年的業務歷史,為超過1,000家臨床機構提供服務。CompuMed的總部設在加利福尼亞州洛杉磯。請訪問CompuMed網站。

Forward-Looking Statements

前瞻性陳述

Statements contained in this report, such as statements about revenue, operations, and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Corporation's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Corporation's filings with the Securities and Exchange Commission and OTC Pink operated by OTCMarkets. All such forward-looking statements are expressly qualified by these cautionary statements. The Corporation expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.

本報告中包含的陳述,如有關收入、運營、收益增長和其他財務結果的陳述,均為前瞻性陳述,符合1995年私人證券訴訟改革法的安全港條款。所有這些前瞻性陳述,包括有關公司計劃、目標、預期和意圖的陳述,主要是基於管理層的期望,受風險和不確定性的影響和制約,這些風險和不確定性可能導致實際結果與此類陳述明示或暗示的結果大不相同。這些陳述會受到不確定因素和風險的影響,包括但不限於產品和服務需求和接受度、技術變化、籌集資金的能力、合適的收購候選者和/或業務夥伴的可用性、經濟條件、競爭和定價的影響、產能和供應限制或困難、政府監管以及公司提交給證券交易委員會和場外交易市場公司運營的OTC Pink的檔案中確定的其他風險。所有這些前瞻性陳述都明確地受到這些警告性聲明的限制。除法律要求外,公司明確不承擔任何義務或承諾公開發布對任何前瞻性陳述的任何更新或修訂,以反映任何此類陳述在本新聞稿日期後所依據的事件、條件或情況。

SOURCE: CompuMed, Inc.

資料來源:CompuMed公司


View source version on accesswire.com:
在Accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論